Simplifying Global Compliance
FDAnews Drug Daily Bulletin
Bayer Submits ‘Son of Nexavar’ Cancer Drug for FDA Approval
Sept. 4, 2012
Bayer HealthCare Pharmaceuticals’ experimental cancer drug regorafenib — viewed as the “son of Nexavar” from Bayer and Onyx Pharmaceuticals — was submitted Aug. 30 for approval to the Food and Drug Administration, the companies said.
San Francisco Business Times
Copyright ©2019. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing